← board
CALC
CalciMedica, Inc.distress 7/10 · high distress / dilution risk$0.76+2%today-89% from 52w high
Nephrology 1
Lead: Acute Kidney Injury
Revenue
pre-revenue
Liquidity
$13M
Runway
0.6 yrs
Shares 1y
+13%
Price & events
-85.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.9%
1D
+9.2%
1W
-5.6%
1M
+30.7%
3M
-85.6%
6M
-82.0%
1Y
-81.0%
2Y
—
5Y
-87.0%
All
Overview
- Market Cap
- $11.97M
- Volume
- 8.83K
- 52 Week Range
- $0.51 – $6.74
- Total Shares
- 15.80M
- Float Shares
- 1.54M
- Short %
- 33.91%
- % Held by Insiders
- 26.50%
- % Held by Institutions
- 35.49%
- RVOL
- 0.00x
- Beta
- 1.11
Pipeline stages · 1 programs
Auxora
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07 | Phase 2 | Auxora | Acute Kidney Injury | 150 | active not recruiting |
Catalyst news & presentations · 3
- 2026-01-28trial discontinuedAuxora · Phase 2 KOURAGE trial discontinued per IDMC safety concern; study design and enrollment criteria to be reevaluated.SEC 8-K
- 2025readoutPhase 1/2Auxora · Phase 1/2 CRSPA trial data expected in 2025SEC 8-K
- October 2024conferencedata presentationsecondaryPhase 2Auxora · Late-breaking data from Phase 2b CARPO trial presented at ACG 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $11 (+1285% upside) · 2 analysts
- 2026-03-05OppenheimerOutperform
- 2026-01-29HC Wainwright & Co.Buy → Neutral
- 2025-05-15HC Wainwright & Co.Buy
- 2025-04-01HC Wainwright & Co.Buy
- 2025-03-04HC Wainwright & Co.Buy
- 2024-12-17LUCID CAPITAL MARKETSBuy
Competitors — Acute Kidney Injury
Recent news
- 2026-07-22Price to earnings forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
- 2026-07-21Enterprise value to revenue forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
- 2026-07-20CalciMedica (CALC): CVI Investments and Heights Capital disclose 5.1% equity stake - Stock Titan
- 2026-07-20CalciMedica (CALC) price target decreased by 24.39% to 10.54 - MSN
- 2026-07-13CalciMedica (NASDAQ: CALC) plans reverse split and warrant votes - Stock Titan
- 2026-07-10CalciMedica (CALC) gains 17.1% shareholder as Alafi Capital ups stake in $2.8M deal - Stock Titan
- 2026-07-10Alafi Capital Discloses Investment at CalciMedica with 17.1% Stake - TradingView
- 2026-07-08CalciMedica, Inc. Files Form 8-K with SEC: Key Company and Stock Information for July 2026 - Minichart
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.